CTOs on the Move

Tapinator

www.tapinator.com

 
Tapinator (Ticker: TAPM) is a global developer and publisher of mobile games on the iOS, Google Play, and Amazon platforms. The Company focuses on operating its own titles, publishing properties where it holds substantial ownership positions, and making strategic investments into promising mobile companies. Tapinator’s owned and operated portfolio includes over 55 mobile gaming titles that, collectively, have over 30 million users. A number of these titles have risen to the top of the mobile leaderboard charts and have been featured by the Apple, Google, and Amazon App Stores. Founded in 2013, Tapinator is headquartered in New York, with development ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tapinator.com
  • 140 West 57th Street; Suite 9C
    New York, NY USA 10019
  • Phone: 914.930.6232

Executives

Name Title Contact Details

Similar Companies

Boyd Industries Inc

Boyd Industries Inc is a Clearwater, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quantum Health

Quantum Health LLC is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Peer Point Medical Education Institute

Peer Point Medical Education Institute is a Evanston, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

fitness marketing systems

fitness marketing systems is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.